BiologicsMD, Inc. Announces Issuance of Patent for PTH-CBD™ in Japan
PTH-CBD™ composition of matter patent recently issued in Japan, supporting the U.S. patent issued in 2013 – additional worldwide patents pending.
Fayetteville, Arkansas (PRWEB) August 14, 2014
BiologicsMD, Inc., a privately held drug discovery company developing unique biologic therapeutics for improving bone health, announced that the Japanese Patent Office issued Patent No. 5520811, entitled "Delivery of Therapeutic Agents by a Collagen Binding Protein," to The Board of Trustees of the University of Arkansas (U.S.), Kitasato University (Japan), and the Montefiore Medical Center (U.S.). This patent supports the U.S. patent issued in 2013 (U.S. Patent No. 8,450,273), entitled "Fusion Proteins of Collagen Binding-Domain and Parathyroid Hormone." BiologicsMD™ is the exclusive licensee of the patent.
BiologicsMD is developing PTH-CBD™ to accelerate the rate of bone fracture repairs and reduce the number of fracture non-unions. Despite current surgical techniques and advanced surgical hardware, further clinical advances are needed to reduce the number of incomplete unions, provide faster fracture healing, and greatly reduce the need for secondary interventions and additional surgeries.
"BiologicsMD is pleased to receive this additional composition of matter patent issued in Japan, and we are looking forward to the remaining patent applications being issued worldwide," stated J. David Owens, Chief Executive Officer of BiologicsMD. "PTH-CBD has a unique profile of selective targeting and strong osteogenic/anabolic properties which enables us to foresee a highly differentiated new product to help treat human disease.”
BiologicsMD, Inc. is an early stage therapeutics company that focuses on novel technologies to actively improve bone health. The company has an exclusive license to develop a new biologic therapeutic, PTH-CBD™, a molecular fusion of PTH (1-33) with the Collagen Binding Domain (CBD) of ColH collagenase. The CBD selectively binds to type I collagen, thus delivering PTH directly to the bone, where it can be most effective in building new bone. This CBD-derived targeting also provides for a long-acting therapeutic, thereby enabling semi-annual dosing for chronic disorders. The company was founded in 2010 and to date, the company has both raised private equity and has been awarded a $2.3 million research contract from the Department of Defense. BiologicsMD™ is a VIC Technology Venture Development™ portfolio company.
For the original version on PRWeb visit: http://www.prweb.com/releases/2014/08/prweb12094978.htm